- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00432211
Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
This study is being undertaken to investigate the efficacy and safety of Juvista (given as an intradermal injection of 200ng/100µl per linear centimetre of wound margin) in the prevention or improvement of scar appearance when administered intradermally to approximated wound margins following surgical scar revision.
In addition, this study will compare the scar revision techniques of complete excision (excision of the entire scar during one surgical procedure) and staged excision (excision of the outmost segments and central core separately).
Studieöversikt
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Manchester, Storbritannien, M13 9XX
- Renovo Clinical Trials Unit
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Subjects aged 18-85 years who have provided written informed consent.
- A body mass index between 15 and 35 kg/m2 .
- Subjects with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol.
- Female subjects of child bearing potential who are using method(s) of contraception acceptable to the Investigator and agree to do so from at least the screening visit until one month after administration of the final study dose.
- Subjects with linear scars that, in the opinion of the Investigator, are suitable for revision by excision and direct closure. The area of scar to be revised must be at least 5cm in length and have at least two comparable areas.
- Subjects, who, in the opinion of the Investigator have stabilised, mature scars.
Exclusion Criteria:
- Subjects who on direct questioning and physical examination have history or evidence of keloid scarring.
- Subjects with scars for revision that cross a joint or are in close proximity to an anatomical structure, which could lead to distortion of the resultant scar.
- Subjects with additional scars less than 3cm away from the area to be revised.
- Subjects with a history of a bleeding disorder.
- Subjects with diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerability or efficacy.
- Subjects who have had surgery in the area to be excised within one year of Day 0.
- Subjects with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
- Subjects who on direct questioning and / or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing.
- Subjects with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.
- Subjects who are taking, or have taken, any investigational drugs including Juvista within 3 months prior to the screening visit.
- Subjects who are taking regular, continuous, oral corticosteroid therapy.
- Subjects who, in the opinion of the Investigator, have significant ongoing psychiatric disorders, which may interfere with the trial assessments / visits.
- Subjects undergoing investigations or changes in management for an existing medical condition.
- Subjects who are or who become pregnant up to and including Day 0 or who are lactating.
- In the opinion of the Investigator, a subject who is not likely to complete the trial for whatever reason.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: 1
Complete Scar Excision
|
Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration. Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration. |
Placebo-jämförare: 2
Staged Excision of scar
|
Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration. Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Investigator scar assessment
Tidsram: up to 7 month visit
|
up to 7 month visit
|
Patient scar assessment
Tidsram: up to 7 month visit
|
up to 7 month visit
|
Independent scar assessment
Tidsram: up to month 7
|
up to month 7
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Local tolerability
Tidsram: up to month 7
|
up to month 7
|
Adverse events
Tidsram: up to month 7
|
up to month 7
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: D A McGrouther, FRCS MD, University of Manchester
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RN1001-319-1009
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Cicatrix
-
Samsung Medical CenterSeoul National University Hospital; Kyunghee University Medical Center; I...OkändHypertrofisk CicatrixKorea, Republiken av
-
Olix Pharmaceuticals, Inc.AvslutadCicatrix, hypertrofiskStorbritannien
-
HugelAvslutadHypertrofiskt ärrKorea, Republiken av
-
SolitonUnited States Naval Medical Center, San DiegoHar inte rekryterat ännuÄrr, hypertrofisk
-
Seton Healthcare FamilyAvslutadHypertrofisk ärrbildningFörenta staterna
-
Hospital Universitari Vall d'Hebron Research InstituteAvslutadCicatrix, hypertrofiskSpanien
-
Nova Scotia Health AuthorityRekrytering
-
Henry Ford Health SystemAktiv, inte rekryterandeÄrr | Hypertrofiskt ärrFörenta staterna
-
Massachusetts General HospitalIndragenHypertrofiska ärrFörenta staterna
-
British Columbia Professional Firefighters' Burn...AvslutadCicatrix | Cicatrix, hypertrofisk | KeloidKanada
Kliniska prövningar på Avotermin
-
RenovoICON Clinical ResearchAvslutadCicatrix | ÅderbråckBelgien, Storbritannien, Lettland, Litauen
-
RenovoAvslutad
-
RenovoAvslutad
-
RenovoAvslutad
-
RenovoOkändCicatrix | NevusStorbritannien
-
RenovoAvslutadFörbättring av ärrStorbritannien
-
RenovoAvslutadKeloidFörenta staterna
-
RenovoAvslutad
-
RenovoAvslutadCicatrixSpanien, Frankrike, Ungern, Italien, Storbritannien, Förenta staterna, Danmark, Tyskland, Lettland, Polen
-
RenovoAvslutadCicatrixStorbritannien